- PR Newswire•13 days agoNanoViricides to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City Today
SHELTON, Conn., Sept. 13, 2016 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), a global leader in nanomedicines that is developing biomimetic anti-viral drugs announced that it will be featured as a presenting company today at the 18th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 11-13, 2016, at Lotte New York Palace Hotel in New York City. Eugene Seymour, MD, MPH, CEO of NanoViricides, will provide an overview of the Company's business and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. Dr Seymour's presentation is scheduled for 10am on Tuesday, September 13th, in the Holmes-I conference room. If you are an institutional investor, and would like to attend the Company's presentation, please click the link www.rodmanevents.com to register for the Rodman & Renshaw conference.
- PR Newswire•last month
SHELTON, Conn., Aug. 25, 2016 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), a global leader in nanomedicines that is developing biomimetic anti-viral drugs reports that Honorable U.S. Senator Chris Murphy visited the Company's new campus in Shelton, CT, on Wednesday, August 24th, 2016. "NanoViricides is exactly the type of innovative company that is driving job creation throughout greater New Haven and the Naugatuck Valley," said Senator Murphy, adding, "I was incredibly impressed by the company and enjoyed hearing from employees during my town hall about how I can best help them and other bioscience entrepreneurs cut through red tape.
- PR Newswire•3 months ago
The Company has previously said that in its HerpeCide™ program, it is currently developing drugs against four different herpesviral disease indications, namely, (i) "Cold sores" caused by Herpes Simplex Virus-1 (HSV-1), (ii) Shingles caused by re-awakening of the chickenpox virus (Varicella Zoster Virus, VZV), (iii) Ocular herpes keratitis which is caused by HSV-1 or HSV-2, and (iv) "Genital ulcers" caused by HSV-2. All of these drugs are being developed as topical treatments. The Company has previously identified a drug candidate that demonstrated substantially complete protection to mice lethally infected with HSV-1 H129 neurotropic strain that produces zosteriform disease in the animals. Since then the Company has undertaken further full fledged drug candidate optimization program which is anticipated to result in a candidates superior to the one in hand.
NanoViricides, Inc. (NNVC)
NYSE MKT - NYSE MKT Delayed Price. Currency in USD
|Bid||1.00 x 1000|
|Day's Range||1.58 - 1.62|
|52wk Range||0.96 - 3.44|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-8.90|
|Avg Vol (3m)||84,161|
|Dividend & Yield||N/A (N/A)|